• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries ADR (NY: TEVA )

    17.46 -0.21 (-1.19%)
    Official Closing Price Updated: 4:10 PM EDT, Oct 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,312,258
    Open 17.55
    Bid (Size) 17.47 (2)
    Ask (Size) 17.50 (9)
    Prev. Close 17.67
    Today's Range 17.41 - 17.63
    52wk Range 8.055 - 19.08
    Shares Outstanding 1,110,352,397
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Teva Launches Generic Version Of Sandostatin In The US
    Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know. 
    Via Benzinga
    Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire

    Performance

    YTD
    +63.64%
    +63.64%
    1 Month
    -5.72%
    -5.72%
    3 Month
    +5.50%
    +5.50%
    6 Month
    +25.97%
    +25.97%
    1 Year
    +74.43%
    +74.43%

    More News

    Read More
    Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
    Via Benzinga
    Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today
    Via Benzinga
    Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
    Via Benzinga
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    Via FinancialNewsMedia
    Exposures Product Safety
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    From FN Media Group LLC
    Via GlobeNewswire
    Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva to Present at the Bank of America 2024 Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
    Via Benzinga
    Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
    Via Benzinga
    JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
    Via Benzinga
    Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
    Via Benzinga
    Organon Stock Sees Relative Strength Rating Rise To 91
    Via Investor's Business Daily
    Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
    Via Benzinga
    Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
    Via Investor's Business Daily
    $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    The 7 Best Under $20 Stocks to Buy in August 2024
    Via InvestorPlace
    Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
    Via PressReach
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.